1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,440 | 3,580 | 24.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.04. | Amplitude Surgical - 9-Months Consolidated Sales for FY 2024-25 of €83.8m, up +6.4% at Constant Exchange Rates | 218 | Business Wire | Sales up +6.6% at constant exchange rates in Q3 FY 2024-25
Consolidated sales for 9 months up+ 6.4% at constant exchange rates to €83.8m
Good momentum in France: sales up +4.7% over... ► Artikel lesen | |
| 17.04. | Zydus Lifesciences Limited announces the execution of undertakings to tender as part of its envisaged tender offer for Amplitude Surgical SA shares | 217 | PR Newswire | AHMEDABAD, India and PARIS, April 17, 2025 /PRNewswire/ -- Following the announcement of its envisaged tender offer on March 11, 2025, Zydus Lifesciences Limited announces the execution of... ► Artikel lesen | |
| 17.04. | Amplitude Surgical Has Been Informed by Zydus Lifesciences Limited of the Execution of Undertakings to Tender as Part of Its Envisaged Tender Offer for Amplitude Surgical SA Shares | 159 | Business Wire | Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible).
Following the announcement of the envisaged tender offer on March 11, 2025 of Zydus Lifesciences Limited... ► Artikel lesen | |
| AMPLITUDE SURGICAL Aktie jetzt für 0€ handeln | |||||
| 26.03. | Amplitude Surgical Announces H1 2024-25 Results: 51.5 M€ Sales and 13.1 M€ EBITDA | 266 | Business Wire | Consolidated sales of €51.5m, up 6.3% at constant exchange rates
EBITDA up 10.6% to €13.1 million, EBITDA margin 25.4%
Current operating income of €6.0 million
Cash position... ► Artikel lesen | |
| 12.03. | XFRA 1AU: WIEDERAUFNAHME/RESUMPTION | 155 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 11.03. | XFRA 1AU: AUSSETZUNG/SUSPENSION | 189 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAMPLITUDE SURGIC.... ► Artikel lesen | |
| 11.03. | Zydus Life inks pact to acquire majority stake in Amplitude Surgical | 2 | capitalmarket.com | ||
| 11.03. | Zydus Enters Exclusive Negotiations with PAI Partners and Other Shareholders to Acquire a Majority stake in Amplitude Surgical, France | 303 | Business Wire | Completion of the transaction to be followed by mandatory simplified tender offer
Zydus has entered into exclusive negotiations to acquire a controlling shareholding in Amplitude Surgical,... ► Artikel lesen | |
| 20.02. | Amplitude Surgical - 1st Half-year 2024-25: Consolidated Sales of €51.5m, +6.3% at Constant Exchange Rates | 274 | Business Wire | Consolidated sales of €51.5 million, up+ 6.3% at constant exchange rates
Good sales growth in France at +4.6%
Strong growth in international business thanks to subsidiaries, with... ► Artikel lesen | |
| 21.11.24 | Amplitude Surgical - First Quarter 2024-25: Consolidated Sales of €21.8m, +7.5% at Constant Exchange Rates | 556 | Business Wire | VALENCE, France--(BUSINESS WIRE)--Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics... ► Artikel lesen | |
| 20.11.24 | Amplitude Surgical Announces Its 2024-25 Financial Calendar | 101 | Business Wire | Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics, announces its financial agenda... ► Artikel lesen | |
| 23.10.24 | Amplitude Surgical - Fiscal Year 2023-24: 106.0 M€ Sales and €27.1m EBITDA | 464 | Business Wire | Consolidated sales of €106.0 million, up 6.3% at constant exchange rates
EBITDA up to €27.1m (+3.7%), EBITDA rate at 25.6%.
Current operating income of €12.7 million
Cash... ► Artikel lesen | |
| 25.07.24 | Amplitude Surgical - Consolidated Annual Sales of €106.0m, up +6.3% at Constant Exchange Rates | 265 | Business Wire | Growth of 7.0% at constant exchange rates in the fourth quarter of FY 2023-2024 and 6.3% for the full year
5.0% sales growth in France
Good momentum outside France, with sales up... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BICO GROUP | 3,550 | -0,39 % | BICO Group Aktie: Strategische Neuausrichtung | BICO Group verkauft MatTek und Visikol für 80 Millionen US-Dollar an Sartorius und fokussiert sich stärker auf Labortechnik. Zudem stehen Personalwechsel und Quartalszahlen an. Verkauf von Tochtergesellschaften... ► Artikel lesen | |
| PING AN HEALTHCARE | 0,800 | 0,00 % | Ping An Healthcare and Technology Company Limited: Ping An Health Reports 25.8% Year-on-Year Revenue Growth in Q1 2025, with Profitability Accelerating | Revenue and Profit Surge, Driven by "AI + Health Care" Value Empowerment
SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Ping An Healthcare and Technology... ► Artikel lesen | |
| ORGANON | 10,535 | -1,03 % | Organon & Co.: Europäische Arzneimittelagentur (EMA) validiert Antrag von Henlius und Organon für Perjeta (Pertuzumab) Biosimilar-Kandidat HLX11 | Shanghai Henlius Biotech, Inc. (2696.HK) und Organon (NYSE: OGN) gaben heute bekannt, dass die Europäische Arzneimittelagentur (EMA) den Antrag auf Marktzulassung (MAA) für HLX11, ein in der Entwicklung... ► Artikel lesen | |
| EMEIS | 10,250 | -3,34 % | emeis: 2024 Full-Year Results | Trajectory for recovery confirmed
Improvement in CSR fundamentals
2024 guidance beaten, with an operational recovery in the second half
2025 EBITDAR expected to rise between +15% and +18%... ► Artikel lesen | |
| CYTOSORBENTS | 0,972 | -4,14 % | CytoSorbents Gains $1.7M Via NJEDA Tax Credit Sale To Fund Strategic Growth | ||
| CLARIANE | 3,780 | -0,37 % | Clariane I 2025 first-quarter revenue | ||
| ARJO | 3,012 | +0,33 % | Arjo AB Aktie: Umsatzplus im überblickbaren Bereich! | Der schwedische Medizintechnikkonzern meldet Umsatzsteigerung trotz volatiler Börsenperformance und erhält wichtige FDA-Zulassung für neue Diagnostiktechnologie. Arjo AB hat für Dienstag, den 29. April... ► Artikel lesen | |
| M3 INC | 11,300 | +1,80 % | MEDIROM Healthcare Technologies Inc.: M3 Group Joins MEDIROM Mother Labs' Series A Financing Round at JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) Pre-Money Valuation | ||
| INTERPACE BIOSCIENCES | 0,785 | 0,00 % | Interpace Biosciences, Inc.: Effective May 2, 2025, Interpace Diagnostics Will No Longer Accept Specimens for PancraGEN, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk | ||
| NYXOAH | 5,290 | -1,67 % | Stifel cuts Nyxoah stock price target to $14, maintains Buy rating | ||
| DYNAVOX GROUP | 5,065 | -2,97 % | Dynavox Group: Tobii Dynavox shows how AI empowers people with disabilities at Microsoft Ability Summit | STOCKHOLM, March 18, 2025 /PRNewswire/ -- Tobii Dynavox, a part of Dynavox Group and the world leader in assistive communication, is today joining Microsoft's Ability Summit, to demonstrate... ► Artikel lesen | |
| VIVANI MEDICAL | 0,900 | -1,10 % | Vivani Medical, Inc.: Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity | ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature... ► Artikel lesen | |
| NANOSONICS | 2,520 | +1,61 % | Why Imricor, Nanosonics, Perpetual, and Tourism Holdings shares are sinking today | ||
| CHINA MEDICAL SYSTEM | 0,970 | -2,51 % | CMS (00867): FIFTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | ||
| NIAGEN BIOSCIENCE | 6,000 | -7,69 % | ChromaDex Aktie: Stabile Wachstumspfade | Das ehemals als ChromaDex bekannte Unternehmen verzeichnet beeindruckendes Umsatzwachstum, erweitert sein Portfolio und erhält wichtige FDA-Anerkennungen für Gesundheitsprodukte. Niagen Bioscience,... ► Artikel lesen |
AMPLITUDE SURGICAL gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 6,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AMPLITUDE SURGICAL finden Sie auf Wallstreet Online.
